On this page
A GI-MAP® test looks for the DNA of specific microbes in one stool sample: bacterial, parasitic and viral pathogens, H. pylori and its virulence genes, a set of commensal and opportunistic bacteria, fungi and yeast, protozoa and worms. It also reports gut function markers such as pancreatic elastase-1, calprotectin, secretory IgA and occult blood. It does not replace a SIBO breath test, and Diagnostic Solutions Laboratory (DSL) lists no mycotoxins or environmental molds such as Aspergillus among its targets.
GutID's Titan-1™ long-read sequencing works the other way, reading the whole bacterial ecosystem rather than a list: it identifies and measures every bacterium in the sample to species, including novel and uncharacterized organisms, from a read of about 2,500 bases, with an approach backed by 30+ peer-reviewed publications. For clinicians who also want targeted markers, GutID Pro adds 65 of them in the same kit.
This guide is for clinicians weighing whether to order a GI-MAP and for patients who have a kit on the way or a report in hand. Marker names follow DSL's own documents at time of writing (October 2026).
GI-MAP at a glance
| Attribute | GI-MAP® (Diagnostic Solutions Laboratory) | GutID | GutID Pro |
|---|---|---|---|
| Who orders it | Healthcare practitioner only; DSL lists it as unavailable to order in New York State | You order it directly; no practitioner order needed | Approved clinicians in the US, for patients 18 and over; not available in New York State |
| Method | Quantitative PCR (qPCR) aimed at the DNA of named organisms, plus stool markers of digestion, immune response and inflammation | Titan-1™ long-read ribosomal sequencing: one continuous read of about 2,500 bases across the full 16S rRNA gene, the ITS and the start of the 23S rRNA gene | Titan-1™ sequencing, with the lab panels run by a CLIA laboratory on a second tube collected at the same time |
| What it measures | Pathogens, H. pylori, selected commensal and opportunistic bacteria, fungi and yeast, two opportunistic viruses, protozoa, worms and intestinal health markers | Every bacterium in the sample to species, including novel and uncharacterized organisms: diversity, balance and each species' relative abundance | The full Complete Microbiome Assessment, plus 65 markers: a GI panel of enteric bacteria, enteric viruses, parasites and Candida; calprotectin; pancreatic elastase-1; fecal occult blood; H. pylori stool antigen; and 31 commensal and dysbiotic bacterial markers |
| Sample | A single stool sample in DSL's vial, mailed at room temperature | At-home stool collection; samples go to a CLIA laboratory in the United States | One collection, two tubes |
| Results time | 7–10 business days, the current turnaround on DSL's site | About 3–4 weeks from when the lab receives the sample | 3–4 weeks, in one report |
| Price | DSL doesn't publish a self-pay price; it files claims to insurance and Medicare | US $399 (Core Gut Insights) or $599 (Complete Microbiome Assessment) at time of writing | Ordered through a clinician account; clinicians sign in for pricing |
| Best suited to | Targeted detection of named organisms and gut function markers, interpreted by a clinician | Seeing the entire bacterial ecosystem and how it shifts over time | Clinicians who want one report covering the ecosystem and targeted markers |
How a GI-MAP works
DSL's test page calls the GI-MAP (GI Microbial Assay Plus) "a diagnostic tool" and explains that it finds microbes with quantitative polymerase chain reaction, which copies and counts DNA sequences unique to each organism on the panel. Each assay is built for one organism or gene. Microbial results are reported as quantities per gram of stool and flagged against reference ranges, and "<dl" on the report means below the detectable limit. Because every target is predefined, the marker list is the scope of the test: an organism that isn't on the panel isn't reported.
What a GI-MAP tests for, category by category
Pathogens
Bacterial pathogens are Campylobacter; C. difficile toxins A and B; several E. coli types (EPEC/EHEC, O157, enteroinvasive E. coli/Shigella, enterotoxigenic LT/ST, and Shiga-like toxin stx1 and stx2); Salmonella; Vibrio cholerae; and Yersinia enterocolitica. Parasitic pathogens are Cryptosporidium, Entamoeba histolytica and Giardia. Viral pathogens are adenovirus 40/41 and norovirus GI/II. DSL notes on the report that "not all individuals with positive findings will present with symptoms," so a finding is read in the context of symptoms and history.
H. pylori, virulence factors and resistance genes
The panel measures Helicobacter pylori DNA and eight virulence factor genes: babA, cagA, dupA, iceA, oipA, vacA, virB and virD. DSL's interpretive guide describes positive virulence factors as showing "the genetic potential" for pathology, not confirmation that disease is present. The report also lists H. pylori antibiotic resistance genes for clarithromycin, amoxicillin, fluoroquinolones and tetracycline, which the guide says are reported only when the H. pylori result is 5.0e2 or greater.
Commensal and keystone bacteria
Nine commensal targets: Bacteroides fragilis, Bifidobacterium spp., Enterococcus spp., Escherichia spp., Lactobacillus spp., Enterobacter spp., Akkermansia muciniphila, Faecalibacterium prausnitzii and Roseburia spp. The report adds Bacteroidetes and Firmicutes at the phylum level and the Firmicutes:Bacteroidetes ratio.
Opportunistic and overgrowth bacteria
DSL sorts these into several groups. Dysbiotic and overgrowth bacteria are Bacillus spp., Enterococcus faecalis, Enterococcus faecium, Morganella spp., Pseudomonas spp. and P. aeruginosa, Staphylococcus spp. and S. aureus, and Streptococcus spp. Commensal overgrowth microbes are Desulfovibrio spp. and the methane-producing Methanobacteriaceae family. Inflammatory and autoimmune-related bacteria are Citrobacter, Klebsiella and Proteus (each at genus level plus one named species) and Mycobacterium avium subsp. paratuberculosis, with a commensal subgroup of Enterobacter, Escherichia, Fusobacterium and Prevotella.
Fungi, yeast and opportunistic viruses
Fungal and yeast targets are Candida spp., Candida albicans, Geotrichum spp., Microsporidium spp. and Rhodotorula spp. Cytomegalovirus and Epstein-Barr virus appear under opportunistic microbes.
Protozoa and worms
Beyond the three parasitic pathogens, the report lists seven protozoa (Blastocystis hominis, Chilomastix mesnili, Cyclospora spp., Dientamoeba fragilis, Endolimax nana, Entamoeba coli and Pentatrichomonas hominis) and five worms: the hookworms Ancylostoma duodenale and Necator americanus, plus Ascaris lumbricoides, Trichuris trichiura and Taenia spp. For more on DNA-based parasite testing at home, see our guide to at-home parasite testing with stool PCR.
Intestinal health markers
On the report these fall into four groups: inflammation (calprotectin); immune response (eosinophil activation protein, anti-gliadin IgA and secretory IgA); digestion (elastase-1 and steatocrit); and GI markers (occult blood by FIT and β-glucuronidase). For background on the inflammation marker, see what fecal calprotectin tells you.
Optional add-ons
Clinicians can add zonulin, a fecal gluten peptide assay, DSL's universal antibiotic resistance gene panel (which DSL says detects 55 genetic elements associated with resistance to 10 antibiotic classes) and StoolOMX™, which DSL describes as 25 bile acids and 9 short- and branched-chain fatty acids.
What a GI-MAP does not tell you
Whether you have SIBO
Small intestinal bacterial overgrowth is defined by excess bacteria in the small bowel. The American College of Gastroenterology's 2020 guideline treats a small-bowel aspirate count of at least 1,000 colony-forming units per milliliter as generally diagnostic, with hydrogen and methane breath testing as the alternative. A stool sample has passed through the large intestine, so it is not a direct sample of the small bowel. DSL's own blog calls the three-hour lactulose breath test "the current diagnostic standard for SIBO within the medical community."
What a GI-MAP can add is context. DSL groups several reported organisms into patterns it associates with IBS and SIBO, including hydrogen sulfide producers such as Desulfovibrio and the methane-producing Methanobacteriaceae, which the guide links to "chronic constipation, as well as some types of SIBO and IBS." See SIBO breath test vs. stool testing.
Mold or mycotoxin exposure
The five fungal targets above make up the whole fungal list on DSL's sample report, which names no mycotoxins and no environmental molds such as Aspergillus or Penicillium; the fungi section of the interpretive guide covers the same organisms. A GI-MAP is therefore not a test for mold exposure; if that is the concern, ask your clinician which testing fits.
The full bacterial community
The commensal and opportunistic targets are a defined list, plus two phyla. A GI-MAP isn't designed to inventory every species in a sample or to measure community-wide diversity, so bacteria outside that list, including ones with no species name yet, don't appear on the report.
When a GI-MAP is the right choice
A GI-MAP fits when a clinician wants targeted, quantitative answers about named organisms from one sample:
- Whether specific pathogens, parasites or H. pylori are present, with H. pylori virulence and resistance genes.
- Markers of digestion, immune response and inflammation reported alongside those organisms.
- Insurance or Medicare billing by the lab; our GI-MAP cost guide covers pricing and ordering.
Anyone with a suspected acute infection or red-flag symptoms, such as blood in the stool, unexplained weight loss, fever, or severe or persistent diarrhea, should see a clinician for diagnostic testing.
When GutID is the better choice
- You want to know what's living in your gut: every species, its share of the community, and the community's diversity and balance.
- You want bacteria no panel lists, including novel and uncharacterized organisms.
- You want to follow change. Each retest shows how the whole ecosystem has shifted.
- You want to order without a practitioner. Core Gut Insights or the Complete Microbiome Assessment ships to you directly, free both ways.
- You're a clinician who wants one collection and one report with the ecosystem and targeted markers together: GutID Pro, ordered through a clinician account.
Why GutID sees more
Every bacterial result on a GI-MAP comes from a target chosen in advance. GutID starts from the whole sample instead, which gives a more complete picture of the bacterial ecosystem than a targeted panel can.
- The whole ecosystem, to species. Titan-1 identifies and measures every bacterium in the sample to species, then reports diversity, balance and each species' relative abundance, as the sample report shows.
- A longer read. One continuous fragment of about 2,500 bases spans the full 16S rRNA gene, the ITS and the start of the 23S rRNA gene: 5–10 times more ribosomal DNA per bacterium than a short-read 16S test, which reads about 250 bases (V4) or 460 (V3–V4). See the science behind Titan-1.
- Not tied to a fixed database. GutID's classifier works from the whole long read rather than matching short markers to a fixed database, so organisms are separated and quantified even when no species name exists.
- Published evidence. The long-read approach behind Titan-1 appears in 30+ peer-reviewed publications, in journals including mBio, Microbial Genomics, Scientific Reports and PLOS ONE. Of the two amplicon methods Gehrig and colleagues tested on clinical-trial samples (Microbial Genomics, 2022), long-read 16S-ITS-23S profiling gave strain-level community resolution and insight into novel taxa; short-read 16S profiling did not.
- Targeted markers in the same kit. GutID Pro adds 65 markers to the Complete Microbiome Assessment, covering many of the categories above, from enteric bacteria, enteric viruses, parasites and Candida to calprotectin, elastase-1, fecal occult blood and H. pylori antigen.
Frequently asked questions
What parasites does a GI-MAP test for?
DSL's sample report lists 15 parasite targets: Cryptosporidium, Entamoeba histolytica and Giardia as pathogens; seven protozoa, including Blastocystis hominis and Dientamoeba fragilis; and five worms: two hookworms, roundworm, whipworm and tapeworm.
Does a GI-MAP test for SIBO?
Not directly. It doesn't measure breath gases or sample the small intestine, and DSL's own blog names the lactulose breath test as the current diagnostic standard for SIBO. It can report methane and hydrogen sulfide producers that DSL associates with SIBO and IBS patterns.
Does a GI-MAP test for H. pylori?
Yes. It measures H. pylori DNA by qPCR, eight virulence factor genes, and resistance genes for clarithromycin, amoxicillin, fluoroquinolones and tetracycline when the H. pylori level reaches 5.0e2 or higher.
Does a GI-MAP test for Candida or mold?
Candida, yes: Candida spp. and Candida albicans are on the panel, with Geotrichum, Microsporidium and Rhodotorula. Mold, no: DSL's sample report lists no mycotoxins and no environmental molds such as Aspergillus or Penicillium.
Is a GI-MAP test worth it?
It depends on the question. For whether specific pathogens, parasites or H. pylori are present, with digestion and inflammation markers, the panel is designed for that. To see the whole bacterial community and how it changes, GutID reads the entire ecosystem, and you can order it yourself.
Is GutID better than GI-MAP?
For seeing the entire bacterial ecosystem, yes. A GI-MAP reports the organisms on its panel; Titan-1 identifies and measures every bacterium in the sample to species, including ones no panel names, from a read covering 5–10 times more ribosomal DNA than a short-read 16S test, backed by 30+ peer-reviewed publications. A GI-MAP is designed for targeted questions about named organisms; GutID Pro adds 65 targeted markers to the ecosystem view. See our GutID vs. GI-MAP comparison.
Sources
- GI-MAP® (GI Microbial Assay Plus) — Diagnostic Solutions Laboratory (accessed October 30, 2026)
- GI-MAP sample report (PDF) — Diagnostic Solutions Laboratory (accessed October 30, 2026)
- GI-MAP Interpretive Guide, 2025 edition (PDF) — Diagnostic Solutions Laboratory (accessed October 30, 2026)
- Microbe Categories and GI-MAP® Patterns Associated with IBS & SIBO (PDF) — Diagnostic Solutions Laboratory (accessed October 30, 2026)
- Beyond Breath Testing: Using the GI-MAP to Uncover the Other Players in SIBO — Diagnostic Solutions Laboratory (accessed October 30, 2026)
- ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth (Pimentel et al., 2020) — American Journal of Gastroenterology (accessed October 30, 2026)
- Finding the right fit: evaluation of short-read and long-read sequencing approaches to maximize the utility of clinical microbiome data (Gehrig et al., 2022) — Microbial Genomics (accessed October 30, 2026)
GutID provides wellness and educational insights and is not a diagnostic test. GI-MAP® and StoolOMX™ are trademarks of their respective owners. GutID is not affiliated with Diagnostic Solutions Laboratory.
This article is for education and is not medical advice. GutID provides wellness and educational insights and is not a diagnostic test.